NCT Number: NCT05489211
Phase: Phase 2
Trial Summary: TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): AstraZeneca
Acronym:
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives